Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01110720 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
A Phase 2 study of Progressive Supranuclear Palsy, sponsored by Allon Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 313
- Enrollment target
- 20
- Study locations
NCT01110720: Completed Phase 2 study of Progressive Supranuclear Palsy, sponsored by Allon Therapeutics.
NCT01110720 is a Phase 2 study of Progressive Supranuclear Palsy that has completed, run by Allon Therapeutics. The registered enrollment target is 313 participants, below the 435-participant average among 18 other Progressive Supranuclear Palsy trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01110720, a Phase 2 study of Progressive Supranuclear Palsy, has completed, sponsored by Allon Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 313 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the safety and efficacy of davunetide for the treatment of Progressive Supranuclear Palsy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Davunetide
Study Locations (20)
California
- USC Keck School of Medicine - Los Angeles
- David Geffen School of Medicine - UCLA - Los Angeles
- UCSD/VA Neurology Service - San Diego
- UCSF Memory and Aging Center - San Francisco
Florida
- Parkinson's Disease and Movement Disorders Center of Boca Raton - Boca Raton
- Mayo Clinic, Florida - Jacksonville
- The Frances J. Zesiewicz Foundation for Parkinson's Disease at USF - Tampa
Arizona
- Muhammed Ali Parkinson Center and Movement Disorders Clinic - Phoenix
- Mayo Clinic, AZ - Scottsdale
Massachusetts
- Massachusetts General Hospital - Boston
- Lahey Clinic - Burlington
Minnesota
- University of Minnesota Department of Neuology - Minneapolis
- Mayo Clinic, Rochester, MN - Rochester
Alabama
- University of Alabama - Birmingham - Birmingham
Colorado
- Colorado Neurological Institute - Rocky Mountain Movement Disorders Ctr, PC - Englewood
Illinois
- University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 313 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
What the finished NCT01110720 record still lists
NCT01110720 is an interventional study that assigns participants to a tested intervention. The registered 313 participants enrollment target is mid-sized for trials with a published cap, below the 435-participant average among 18 other Progressive Supranuclear Palsy trials with a reported enrollment target (28% lower).
The record links to 1 condition, with Progressive Supranuclear Palsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01110720 names 20 study sites across 12 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT01110720 about?
NCT01110720 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy". The purpose of the study is to evaluate the safety and efficacy of davunetide for the treatment of Progressive Supranuclear Palsy.
What is the current status of trial NCT01110720?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 313 participants. The study started on 2010-10. Estimated completion is 2012-12.
What conditions does trial NCT01110720 study?
This clinical trial studies the following conditions: Progressive Supranuclear Palsy.
What interventions are being tested in trial NCT01110720?
The interventions under investigation include: Placebo (DRUG), Davunetide (DRUG).
Who is sponsoring clinical trial NCT01110720?
This trial is sponsored by Allon Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01110720 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Progressive Supranuclear Palsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01110720's enrollment target sits among peer trials
313 8th of 18 higher than 11 of 18 other Progressive Supranuclear Palsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Progressive Supranuclear Palsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
ACTIVE NOT RECRUITING · Phase 2
-
AMX0035 and Progressive Supranuclear Palsy
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Coenzyme Q10 in PSP and CBD
COMPLETED · Phase 2
-
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
RECRUITING
-
Gait Analysis in Neurological Disease
RECRUITING
-
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00595491 · 313 participants · Phase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
- NCT03866382 · 314 participants · Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- NCT04500756 · 314 participants · Phase 2
Limiting AAA With Metformin (LIMIT) Trial
- NCT06167746 · 314 participants · Phase 3
iCare4Me Transitions
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia